Figure 9.
Therapeutic and prophylactic effects of purified mAb against lethal infections with H5N1 avian influenza virus. (A) Twenty-four hours before intranasal infection with 2 × 105 PFU of A/Hong Kong/213/2003 (H5N1) virus, three groups (five mice each) of BALB/c mice were injected intraperitoneally with PBS as a control, or 15 or 5 μg of V3-2G6 generated from a subject vaccinated with the pdmH1N1 vaccine. The data shows survival rates and average weight at over 14 days. (B,C) Groups of five mice were infected intranasally with 2 × 105 PFU of A/Hong Kong/213/2003 (H5N1) virus and (B) treated after 24 h with 150 or 300 μg of V3-2G6 or after 48 h with 300 or 600 μg of V3-2G6 and (C) treated after 24 h with 150, 75 or 37.5 μg of V3-2G6.